PICO Advisory Sub-Committee – Applications Considered
- 1522 – PDL1 immunohistochemistry testing for access to pembrolizumab as first-line therapy for patients with recurrent (not amenable to local treatment) or metastatic head and neck squamous cell carcinoma
- 1585 – Genetic testing for the diagnosis of early-onset or familial neuromuscular disorders
- 1600 – Genetic testing for inherited kidney disease (other than Alport syndrome)
- 1608 – Human tissue (amnion membrane) for topical treatment of ophthalmic disorders, and wounds
- 1613 – Permanent acute coronary syndrome event detector (insertion, removal or replacement of) for monitoring of the heart's electrical activity
- 1614 – Magnetic resonance-guided focused ultrasound for patients with essential tremor
- 1615 – Transcatheter occlusion of left atrial appendage for patients with non-valvular atrial fibrillation
- 1617 – BRAF V600 mutation testing to determine eligibility for PBS access to Braftovi (encorafenib) in patients with metastatic colorectal cancer (stage IV)
- 1618 – Testing of tumour prostate tissue to detect BRCA1/2 or ATM gene mutations in men with metastatic castration-resistant prostate cancer to determine eligibility for PBS olaparib
- 1619 – Testing of blood to detect germline BRCA1 or BRCA2 gene mutations in patients with metastatic pancreatic cancer to determine eligibility for PBS olaparib
- 1620 – Magnetic resonance image guided radiation therapy